Service d'Endocrinologie-Métabolisme, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Nutr Metab Cardiovasc Dis. 2011 Oct;21(10):817-22. doi: 10.1016/j.numecd.2010.02.023. Epub 2010 Aug 3.
Serum levels of ICAM-1 (Inter Cellular Adhesion Molecule-1), VCAM-1 (Vascular cell Adhesion Molecule-1-I), TIMP-1 (tissue inhibitor of metalloproteinases 1) and MMP-9 (Metalloproteinase 9) are well established markers of inflammation. The physiopathological link between inflammation, atherosclerosis and autoimmunity is well demonstrated. However, serum levels of these biomarkers in patients with autoimmune-mediated dysthyroidism, including their evolution after improvement of the thyroid disorder have not been assessed. So, we evaluated the circulating levels of these markers in autoimmune and in non-autoimmune-mediated dysthyroid patients, and their evolution after treatment of thyroid disease. We conducted a prospective study to evaluate these markers before and after treatment in hyperthyroid patients (n = 33; 28 patients with autoimmune disease), hypothyroid patients (n = 38; 33 patients with autoimmune disease) and euthyroid subjects (n = 33). At baseline, serum levels of ICAM-1, VCAM-1 and TIMP-1 were significantly elevated in patients with hyperthyroidism as compared to euthyroid and hypothyroid patients (respectively p = 0.0005 and p < 0.0001). In multivariate analysis, the differences remained significant for VCAM-1 and TIMP-1. Median levels of ICAM-1, VCAM-1 and TIMP-1 were significantly higher in patients with autoimmune-mediated dysthyroidism compared to euthyroid patients (respectively p < 0.0001 and p = 0.002). In hyperthyroid patients, ICAM-1, VCAM-1 and TIMP-1 concentrations fell significantly after they had become euthyroid (respectively p = 0.0006; p < 0.0001 and p = 0.0009), although VCAM-1 values remained higher than those observed in the control group (p = 0.005). We found that autoimmune-mediated dysthyroidism were associated with increased peripheral blood concentrations of VCAM-1, ICAM-1 and TIMP-1. Whether these biological abnormalities translate into increase intima remodelling and atherosclerosis remains to be studied.
血清细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)、基质金属蛋白酶组织抑制剂-1(TIMP-1)和基质金属蛋白酶-9(MMP-9)的水平是炎症的公认标志物。炎症、动脉粥样硬化和自身免疫之间的病理生理学联系已得到充分证明。然而,自身免疫性甲状腺功能障碍患者的这些生物标志物的血清水平,包括甲状腺疾病改善后的这些标志物的变化,尚未得到评估。因此,我们评估了自身免疫性和非自身免疫性甲状腺功能障碍患者的这些标志物的循环水平,以及甲状腺疾病治疗后的这些标志物的变化。我们进行了一项前瞻性研究,以评估甲状腺功能亢进症患者(n = 33;28 例为自身免疫性疾病)、甲状腺功能减退症患者(n = 38;33 例为自身免疫性疾病)和甲状腺功能正常患者(n = 33)在治疗前后的这些标志物。在基线时,与甲状腺功能正常和甲状腺功能减退的患者相比,甲状腺功能亢进症患者的血清 ICAM-1、VCAM-1 和 TIMP-1 水平显著升高(分别为 p = 0.0005 和 p < 0.0001)。在多变量分析中,VCAM-1 和 TIMP-1 的差异仍然显著。与甲状腺功能正常的患者相比,自身免疫性甲状腺功能障碍患者的 ICAM-1、VCAM-1 和 TIMP-1 水平中位数显著升高(分别为 p < 0.0001 和 p = 0.002)。在甲状腺功能亢进症患者中,当他们变为甲状腺功能正常后,ICAM-1、VCAM-1 和 TIMP-1 的浓度显著下降(分别为 p = 0.0006;p < 0.0001 和 p = 0.0009),尽管 VCAM-1 值仍高于对照组(p = 0.005)。我们发现,自身免疫性甲状腺功能障碍与外周血 VCAM-1、ICAM-1 和 TIMP-1 浓度升高有关。这些生物学异常是否转化为内膜重塑和动脉粥样硬化的增加仍有待研究。